Search

Your search keyword '"Graham P Cook"' showing total 39 results

Search Constraints

Start Over You searched for: Author "Graham P Cook" Remove constraint Author: "Graham P Cook" Topic hematology Remove constraint Topic: hematology
39 results on '"Graham P Cook"'

Search Results

1. Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study

2. Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

Catalog

Books, media, physical & digital resources

3. Abstracts

4. PS1425 RESULTS OF THE DARATUMUMAB MONOTHERAPY EARLY ACCESS TREATMENT PROTOCOL (EAP) IN PATIENTS FROM EUROPE AND RUSSIA WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

5. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: conditioning protocols and donor selection algorithms

6. In pursuit of the allo-immune response in multiple myeloma: where do we go from here?

7. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study

8. Natural killer (NK) cell function in paroxysmal nocturnal hemoglobinuria: A deficiency of NK cells, but not an NK cell deficiency

9. Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning - evidence for a superior outcome using melphalan combined with total body irradiation

10. Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation

11. Autologous stem cell transplantation (ASCT) in patients with POEMS syndrome results in durable symptomatic disease control: A retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancies Working Party of the EBMT

12. Altered natural killer cell subset homeostasis and defective chemotactic responses in paroxysmal nocturnal hemoglobinuria

13. EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era

14. Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation

15. Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study

16. Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA

17. The clinical features and outcome of 2009 H1N1 influenza infection in allo-SCT patients: a British Society of Blood and Marrow Transplantation study

18. Prognostic impact of serum ferritin concentration on survival following reduced-intensity conditioned allogeneic haemopoietic SCT

19. The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study

20. Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial

21. Haematopoietic repopulating activity in human cord blood CD133+ quiescent cells

22. An analysis of the optimal timing of peripheral blood stem cell harvesting following priming with cyclophosphamide and G-CSF

23. The impact of normal plasma cell recovery on progression-free and overall survival in myeloma patients after ASCT

24. Molecular risk stratification of 1,036 cases from the NCRI Myeloma XI trial using the all-molecular diagnostic tool MyMaP (Myeloma MLPA and translocation PCR)

25. The spectrum and clinical impact of epigenetic modifier mutations in myeloma

26. The quadruplet KCRD (carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone) is safe and well tolerated as induction therapy for newly diagnosed, transplant eligible, myeloma patients

27. Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI trial

28. Lessons for Improved Care (LIC)—a pre-emptive risk management strategy which encourages continuous learning in centers performing peripheral blood and Bone Marrow Transplantation

29. A family with Papillon-Lefevre syndrome reveals a requirement for cathepsin C in granzyme B activation and NK cell cytolytic activity

30. Lymphodepletion in the ApcMin/+ mouse model of intestinal tumorigenesis

31. Unsuccessful stem cell remobilization for autologous transplantation is predicted by renal impairment and a stem cell yield ⩽0.5 × 106 CD34+ cells/kg at first mobilization

33. Th17 Cells Are Increased in the Bone Marrow but Not the Peripheral Blood in Multiple Myeloma and Demonstrate Defective Functionality and Aberrant Phenotypes

35. A236 Second Autologous Transplantation After Bortezomib-Based Re-Induction Therapy: The UK Experience

36. Erratum: Voriconazole or itraconazole for antifungal prophylaxis in patients with grade II-IV acute or extensive chronic graft-versus-host disease

37. A161 The PAD (Ireland) Study for Patients with Refractory and Relapsed Myeloma: An Update

38. A Comparison of Stem Cell Source in Recipients of T-Cell Depleted Myeloablative Transplants for Leukaemia: No Difference in Mortality Using BM or PBSC